MCID: NSS002
MIFTS: 49

Neisseria Meningitidis Infection

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Neisseria Meningitidis Infection

MalaCards integrated aliases for Neisseria Meningitidis Infection:

Name: Neisseria Meningitidis Infection 53
Meningococcal Disease 53 3
Meningococcal Infections 73
Meningococcal Diseases 55

Classifications:



External Ids:

ICD10 33 A39.9
UMLS 73 C0025303

Summaries for Neisseria Meningitidis Infection

CDC : 3 Meningococcal disease can refer to any illness caused by the type of bacteria called Neisseria meningitidis, also known as meningococcus [muh-ning-goh-KOK-us]. These illnesses are often severe and can be deadly. They include infections of the lining of the brain and spinal cord (meningitis) and bloodstream infections (bacteremia or septicemia).

MalaCards based summary : Neisseria Meningitidis Infection, also known as meningococcal disease, is related to meningococcal meningitis and meningococcemia, and has symptoms including fever and pruritus. An important gene associated with Neisseria Meningitidis Infection is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Influenza A. The drugs Ciprofloxacin and Histidine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and b cells, and related phenotypes are hematopoietic system and immune system

Related Diseases for Neisseria Meningitidis Infection

Diseases related to Neisseria Meningitidis Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 meningococcal meningitis 32.6 CFP MBL2
2 meningococcemia 32.2 CFP IL1RN MBL2
3 pneumonia 29.0 LACTB MBL2 TLR2 TLR4
4 meningitis 28.2 CFP FCGR2A LACTB MBL2 OMP TLR2
5 complement component 8 deficiency 11.5
6 properdin deficiency 11.2
7 meningococcal infection 11.2
8 c3 glomerulopathy 10.7 C3 CFP
9 scabies 10.7 CFP MBL2
10 peripheral retinal degeneration 10.6 MBL2 ROM1
11 deafness, autosomal recessive 24 10.6 EZR MSN
12 mannose-binding lectin deficiency 10.6 CFP MBL2
13 complement component 3 deficiency 10.6 C3 CFP
14 complement factor i deficiency 10.6 C3 CFP
15 coccidioidomycosis 10.5 MBL2 TLR4
16 pouchitis 10.4 IL1RN TLR4
17 complement deficiency 10.4 C3 CFP MBL2
18 haemophilus influenzae 10.3 OMP TLR2
19 cryopyrin-associated periodic syndrome 10.3 IL1R1 IL1RN
20 trench fever 10.3 TLR2 TLR4
21 schnitzler syndrome 10.3 IL1R1 IL1RN
22 neurofibromatosis, type ii 10.2 EZR MSN TLR2
23 streptococcal meningitis 10.2 CFP IL1R1 MBL2
24 acute cervicitis 10.2 TLR2 TLR4
25 bacteremia 2 10.2 LACTB MBL2
26 suppurative otitis media 10.2 TLR2 TLR4
27 penicilliosis 10.1 TLR2 TLR4
28 vulvar vestibulitis syndrome 10.1 IL1R1 IL1RN MBL2
29 aggressive periodontitis 10.1 FCGR2A IL1RN TLR4
30 myositis fibrosa 10.1 TLR2 TLR4
31 prosthetic joint infection 10.0 MBL2 TLR2 TLR4
32 tularemia 10.0 MBL2 TLR2
33 bacterial vaginosis 10.0 MBL2 TLR2 TLR4
34 membranoproliferative glomerulonephritis 10.0 C3 CD46 CFP
35 adult-onset still's disease 10.0 FCGR2A IL1R1 IL1RN
36 afibrinogenemia 10.0 C3 CD46 CFP
37 aspergillosis 10.0 MBL2 TLR2 TLR4
38 extrapulmonary tuberculosis 10.0 IL1RN MBL2 TLR2
39 mycobacterium tuberculosis 1 10.0 MBL2 TLR2 TLR4
40 aneurysm 9.9
41 endotheliitis 9.9
42 nasopharyngitis 9.9
43 cardiac tamponade 9.9
44 waterhouse-friderichsen syndrome 9.9
45 autoinflammation, lipodystrophy, and dermatosis syndrome 9.9 IL1R1 IL1RN TLR4
46 enterocolitis 9.9 C3 CD46 TLR4
47 periodontal disease 9.8 IL1RN TLR2 TLR4
48 behcet syndrome 9.8 IL1RN MBL2 TLR4
49 endocarditis 9.8 FCGR2A LACTB TLR2
50 alveolar echinococcosis 9.8 TLR2 TLR4

Graphical network of the top 20 diseases related to Neisseria Meningitidis Infection:



Diseases related to Neisseria Meningitidis Infection

Symptoms & Phenotypes for Neisseria Meningitidis Infection

UMLS symptoms related to Neisseria Meningitidis Infection:


fever, pruritus

MGI Mouse Phenotypes related to Neisseria Meningitidis Infection:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 IL1RN MBL2 TLR2 TLR4 C3 DHPS
2 immune system MP:0005387 10.02 C3 CFP DHPS EZR FCGR2A IL1R1
3 cardiovascular system MP:0005385 10.01 C3 CD46 CFP IL1R1 IL1RN ROM1
4 mortality/aging MP:0010768 9.96 C3 CFP DHPS EZR FCGR2A IL1R1
5 normal MP:0002873 9.76 C3 CFP DHPS IL1R1 MSN OMP
6 renal/urinary system MP:0005367 9.43 C3 DHPS IL1R1 MBL2 TLR2 TLR4
7 skeleton MP:0005390 9.17 C3 CFP FCGR2A IL1R1 IL1RN TLR2

Drugs & Therapeutics for Neisseria Meningitidis Infection

Drugs for Neisseria Meningitidis Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Histidine Approved, Nutraceutical Phase 4 71-00-1 6274
3
Lactitol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 585-86-4 3871
4 Complement Factor H Phase 4
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antibodies Phase 4,Phase 3,Phase 2
8 Immunoglobulins Phase 4,Phase 3,Phase 2
9 Cathartics Phase 4,Phase 3,Phase 2,Not Applicable
10 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Topoisomerase Inhibitors Phase 4
14 Anti-Bacterial Agents Phase 4,Phase 3
15 Anti-Infective Agents Phase 4,Phase 3
16 Laxatives Phase 4,Phase 3,Phase 2,Not Applicable
17
Hydroxocobalamin Approved Phase 3,Phase 2 13422-51-0 11953898 44475014
18
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
19
Iron Approved Phase 3,Phase 2 7439-89-6 23925
20
Acetaminophen Approved Phase 3 103-90-2 1983
21
Edetic Acid Approved, Vet_approved Phase 3,Phase 2 60-00-4, 62-33-9 6049
22
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
23
Pentetic acid Approved Phase 3,Phase 2 67-43-6
24
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2 68-19-9 44176380
25 Vitamin B 12 Phase 3,Phase 2
26 Analgesics Phase 3
27 Fibrinolytic Agents Phase 3
28 Adjuvants, Immunologic Phase 2, Phase 3,Phase 1
29 Chelating Agents Phase 3,Phase 2
30 Complement System Proteins Phase 3
31 Analgesics, Non-Narcotic Phase 3
32 Antacids Phase 2, Phase 3,Phase 1
33 PENTA Phase 3,Phase 2
34 Peripheral Nervous System Agents Phase 3
35 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
36 Anticoagulants Phase 3
37 Antidotes Phase 3,Phase 2
38 Iron Chelating Agents Phase 3,Phase 2
39 Protective Agents Phase 3,Phase 2
40 Antipyretics Phase 3,Phase 2
41 Anti-Ulcer Agents Phase 2, Phase 3,Phase 1
42 Vitamin B12 Nutraceutical Phase 3,Phase 2
43
Cobalamin Nutraceutical Phase 3,Phase 2 13408-78-1 6438156
44
Aluminum sulfate Approved Phase 2 10043-01-3
45 Hops Approved, Nutraceutical Phase 1
46
Salmon Calcitonin Approved, Investigational 47931-85-1 16129616
47
Calcitonin gene-related peptide Investigational 83652-28-2
48 calcitonin
49 Natriuretic Agents Not Applicable
50 Natriuretic Peptide, Brain Not Applicable

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
2 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
3 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
4 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
5 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
6 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Completed NCT02446691 Phase 4
7 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
8 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Completed NCT01766206 Phase 4
9 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
10 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
11 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
12 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
13 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
14 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
15 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
16 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
17 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Completed NCT00310635 Phase 4
18 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed NCT00850603 Phase 4
19 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
20 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
21 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
22 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
23 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
24 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
25 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
26 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
27 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
28 Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
29 Ciprofloxacin for the Prevention of Meningococcal Meningitis Completed NCT02724046 Phase 4 Ciprofloxacin
30 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
31 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
32 A Sourcing Study to Collect Human Blood Samples From Healthy Adults Recruiting NCT03493919 Phase 4
33 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Active, not recruiting NCT03125616 Phase 4
34 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
35 A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Enrolling by invitation NCT02868970 Phase 4
36 Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Not yet recruiting NCT03431675 Phase 4 Ciprofloxacin
37 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination Unknown status NCT01777308 Phase 3
38 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
39 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3
40 Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Completed NCT01641042 Phase 3
41 Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Completed NCT01682876 Phase 3
42 Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
43 One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age Completed NCT01139021 Phase 3
44 A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Completed NCT01478347 Phase 3
45 Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers Completed NCT00847145 Phase 3
46 Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules Completed NCT00661713 Phase 2, Phase 3
47 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Chil Completed NCT01339923 Phase 3
48 Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 Completed NCT01148524 Phase 2, Phase 3
49 Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Completed NCT01642589 Phase 3
50 Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Completed NCT02173704 Phase 3

Search NIH Clinical Center for Neisseria Meningitidis Infection

Genetic Tests for Neisseria Meningitidis Infection

Anatomical Context for Neisseria Meningitidis Infection

MalaCards organs/tissues related to Neisseria Meningitidis Infection:

41
Brain, Spinal Cord, B Cells, Testes, Bone, Endothelial, Kidney

Publications for Neisseria Meningitidis Infection

Articles related to Neisseria Meningitidis Infection:

(show top 50) (show all 139)
# Title Authors Year
1
Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection. ( 29977064 )
2018
2
Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies. ( 28368462 )
2017
3
Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management. ( 28213751 )
2017
4
Complement factor 5 (C5) p.A252T mutation is prevalent in, but not restricted to, sub-Saharan Africa: implications for the susceptibility to meningococcal disease. ( 28369827 )
2017
5
Innate immune recognition and inflammation in Neisseria meningitidis infection. ( 28334203 )
2017
6
Invasive meningococcal disease with pericarditis and pneumonia: A rare presentation in childhood. ( 27077027 )
2016
7
Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies. ( 27805046 )
2016
8
A Case-Control Study on the Risk Factors for Meningococcal Disease among Children in Greece. ( 27351742 )
2016
9
Antibodies for Rickettsia spp. in patients with negative serology for dengue virus, leptospirosis, and meningococcal disease in municipalities of SALo Paulo State, Brazil. ( 27812650 )
2016
10
Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. ( 26688376 )
2016
11
Confirmation of Host Genetic Determinants in the CFH Region and Susceptibility to Meningococcal Disease in a Central European Study Sample. ( 26135246 )
2015
12
Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease. ( 26487381 )
2015
13
Neisseria meningitidis infection: who, when and where? ( 26190347 )
2015
14
Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series. ( 26308192 )
2015
15
A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. ( 25534848 )
2015
16
The case of a new sequence type 7 serogroup X Neisseria meningitidis infection in China: may capsular switching change serogroup profile? ( 25449237 )
2014
17
Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection. ( 24706855 )
2014
18
Comparison of cytokine gene polymorphisms among Greek patients with invasive meningococcal disease or viral meningitis. ( 23378564 )
2013
19
Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review. ( 22296677 )
2012
20
Complete deficiency of the sixth complement component (C6Q0), susceptibility to Neisseria meningitidis infections and analysis of the frequencies of C6Q0 gene defects in South Africans. ( 22288589 )
2012
21
A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. ( 21990375 )
2012
22
Complement and mannose-binding lectin 2 polymorphism in meningococcal disease. ( 23289185 )
2012
23
Complement component C5 and C6 mutation screening indicated in meningococcal disease in South Africa. ( 22668955 )
2012
24
Polymorphisms in PARP, IL1B, IL4, IL10, C1INH, DEFB1, and DEFA4 in meningococcal disease in three populations. ( 20016407 )
2010
25
Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine. ( 20463106 )
2010
26
Spotted fever: meningococcal disease and petechiae. ( 20362748 )
2010
27
Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. ( 20334849 )
2010
28
Neuropeptide alpha-MSH exerts pro-inflammatory effects on Neisseria meningitidis infection in vitro. ( 19685205 )
2010
29
Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. ( 20694013 )
2010
30
Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. ( 19931914 )
2010
31
Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. ( 19036641 )
2009
32
Sequential analysis of biomarkers in cerebrospinal fluid and serum during invasive meningococcal disease. ( 19205764 )
2009
33
Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease. ( 19707127 )
2009
34
A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. ( 19067670 )
2009
35
CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. ( 19809507 )
2009
36
Pentraxin 3 and C-reactive protein in severe meningococcal disease. ( 18650775 )
2009
37
Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease. ( 17960155 )
2008
38
Cardiac tamponade as a delayed presentation of Neisseria meningitidis infection in a 5-month-old infant. ( 17413432 )
2007
39
Meningococcal disease associated with an acute post-streptococcal complement deficiency. ( 17294226 )
2007
40
Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. ( 17484222 )
2007
41
Usefulness of pulsed-field gel electrophoresis in tracking two outbreaks of invasive meningococcal disease serogroup C in British Columbia. ( 18978987 )
2007
42
Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. ( 17692067 )
2007
43
Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease. ( 17083016 )
2006
44
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. ( 16677307 )
2006
45
Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. ( 16758417 )
2006
46
Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. ( 16395111 )
2006
47
Neisseria meningitidis infection of human endothelial cells interferes with leukocyte transmigration by preventing the formation of endothelial docking structures. ( 16717131 )
2006
48
Antigenic shift and increased incidence of meningococcal disease. ( 16586364 )
2006
49
Case of Waterhouse Friderichsen Syndrome during outbreak of meningococcal disease in Delhi in May 2005. ( 16749283 )
2005
50
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. ( 16137345 )
2005

Variations for Neisseria Meningitidis Infection

Expression for Neisseria Meningitidis Infection

Search GEO for disease gene expression data for Neisseria Meningitidis Infection.

Pathways for Neisseria Meningitidis Infection

Pathways related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 C3 CD46 CFP FCGR2A IL1R1 IL1RN
2
Show member pathways
12.32 C3 CD46 CFP MSN TLR2 TLR4
3
Show member pathways
12.29 IL1R1 TLR2 TLR4
4 12.08 EZR MSN TLR2 TLR4
5
Show member pathways
12.01 IL1R1 IL1RN TLR2
6
Show member pathways
11.98 C3 FCGR2A TLR2 TLR4
7
Show member pathways
11.97 IL1R1 TLR2 TLR4
8 11.92 C3 FCGR2A TLR2 TLR4
9
Show member pathways
11.89 C3 CD46 MBL2
10 11.86 C3 CD46 MBL2
11
Show member pathways
11.79 IL1R1 TLR2 TLR4
12 11.77 FCGR2A IL1R1 TLR4
13
Show member pathways
11.75 C3 CD46 CFP MBL2
14 11.65 IL1R1 TLR2 TLR4
15
Show member pathways
11.58 C3 CD46 CFP MBL2
16 11.38 C3 FCGR2A MBL2
17 11.35 C3 TLR2 TLR4
18 11.2 C3 FCGR2A MBL2 TLR2 TLR4
19 11.19 C3 FCGR2A TLR2 TLR4
20 10.96 IL1R1 TLR2

GO Terms for Neisseria Meningitidis Infection

Cellular components related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic component of plasma membrane GO:0031226 9.32 TLR2 TLR4
2 microvillus membrane GO:0031528 9.26 EZR MSN
3 uropod GO:0001931 9.16 EZR MSN
4 cell surface GO:0009986 9.1 CD46 IL1R1 MBL2 MSN TLR2 TLR4
5 invadopodium GO:0071437 8.96 EZR MSN

Biological processes related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.91 C3 IL1RN TLR2 TLR4
2 immune system process GO:0002376 9.89 C3 CD46 MBL2 TLR2 TLR4
3 complement activation, classical pathway GO:0006958 9.8 C3 CD46 MBL2
4 regulation of complement activation GO:0030449 9.77 C3 CD46 CFP
5 positive regulation of gene expression GO:0010628 9.72 CD46 EZR MSN TLR2 TLR4
6 complement activation GO:0006956 9.71 C3 CFP MBL2
7 positive regulation of interleukin-8 production GO:0032757 9.64 TLR2 TLR4
8 leukocyte cell-cell adhesion GO:0007159 9.64 EZR MSN
9 positive regulation of interferon-beta production GO:0032728 9.63 TLR2 TLR4
10 positive regulation of interleukin-12 production GO:0032735 9.63 TLR2 TLR4
11 innate immune response GO:0045087 9.63 C3 CD46 CFP MBL2 TLR2 TLR4
12 regulation of cell size GO:0008361 9.62 EZR MSN
13 positive regulation of chemokine production GO:0032722 9.61 TLR2 TLR4
14 establishment of endothelial barrier GO:0061028 9.6 EZR MSN
15 establishment of epithelial cell apical/basal polarity GO:0045198 9.58 EZR MSN
16 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.58 TLR2 TLR4
17 complement activation, alternative pathway GO:0006957 9.57 C3 CFP
18 I-kappaB phosphorylation GO:0007252 9.56 TLR2 TLR4
19 positive regulation of cellular protein catabolic process GO:1903364 9.55 EZR MSN
20 regulation of cytokine secretion GO:0050707 9.52 TLR2 TLR4
21 cellular response to lipoteichoic acid GO:0071223 9.51 TLR2 TLR4
22 gland morphogenesis GO:0022612 9.48 EZR MSN
23 positive regulation of early endosome to late endosome transport GO:2000643 9.46 EZR MSN
24 positive regulation of protein localization to early endosome GO:1902966 9.43 EZR MSN
25 membrane to membrane docking GO:0022614 9.4 EZR MSN
26 regulation of organelle assembly GO:1902115 9.37 EZR MSN
27 interleukin-10 production GO:0032613 9.26 CD46 TLR2
28 positive regulation of interleukin-10 production GO:0032733 9.13 CD46 TLR2 TLR4
29 immune response GO:0006955 9.1 C3 CFP IL1R1 IL1RN TLR2 TLR4

Molecular functions related to Neisseria Meningitidis Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.33 CD46 TLR2 TLR4
2 signaling receptor binding GO:0005102 9.26 C3 MBL2 MSN TLR4
3 lipopolysaccharide receptor activity GO:0001875 8.62 TLR2 TLR4

Sources for Neisseria Meningitidis Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....